Otilonium Bromide: Antimuscarinic Agent for Advanced Neuroscience Research

Executive Summary: Otilonium Bromide (C29H43BrN2O4, MW 563.57) is a selective antimuscarinic agent that inhibits acetylcholine receptors (AChR), enabling direct modulation of cholinergic signaling in both neuroscience and smooth muscle research (APExBIO). It exhibits high solubility (≥28.18 mg/mL in DMSO, ≥91 mg/mL in ethanol) and purity (≥98%), supporting a wide range of experimental workflows (A-740003.com). Its mechanism is well-characterized: Otilonium Bromide is a non-selective muscarinic receptor antagonist, preventing acetylcholine-mediated smooth muscle contraction (Vijayan et al., 2021). APExBIO supplies Otilonium Bromide (SKU: B1607) specifically for research, not clinical applications. Storage at -20°C ensures compound stability for short-term experiments.

Biological Rationale

Cholinergic signaling, mediated via acetylcholine and its receptors (AChRs), orchestrates muscle contraction, neuronal transmission, and gastrointestinal motility (Vijayan et al., 2021). Dysregulation of muscarinic receptor pathways is implicated in smooth muscle spasm and various motility disorders. Targeted inhibition of these pathways, using agents such as Otilonium Bromide, enables the dissection of muscarinic receptor functions in physiologic and pathophysiologic states. Controlled antagonism of muscarinic AChRs is essential for creating reproducible models in neuroscience and gastrointestinal research. Compared to broader spectrum antispasmodics, Otilonium Bromide’s receptor selectivity reduces off-target effects, enabling precise experimental interpretation (acetyl-angiotensinogen.com).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (AChRs) located on smooth muscle and neuronal tissues. By binding to the receptor’s orthosteric site, it blocks acetylcholine-induced receptor activation, leading to inhibition of intracellular signaling cascades that mediate muscle contraction. This results in a potent antispasmodic effect, particularly in gastrointestinal smooth muscle systems. The inhibition is reversible and concentration-dependent. Otilonium Bromide does not significantly inhibit nicotinic acetylcholine receptors or other unrelated receptor types at research-relevant concentrations (a-317491.com). The compound’s high water and ethanol solubility (≥55.8 mg/mL and ≥91 mg/mL, respectively) facilitates its use in diverse in vitro and in vivo assays (APExBIO).

Evidence & Benchmarks

• Otilonium Bromide inhibits muscarinic AChRs, leading to reduced smooth muscle contractility in ex vivo tissue models (Vijayan et al., 2021, DOI:10.1007/s42485-021-00059-w).
• High solubility in water (≥55.8 mg/mL), DMSO (≥28.18 mg/mL), and ethanol (≥91 mg/mL) allows for flexible compound preparation for pharmacological assays (APExBIO).
• Purity specification of ≥98% ensures minimal confounding by impurities in receptor pharmacology studies (a-740003.com).
• Otilonium Bromide’s antimuscarinic mechanism has been validated in multiple in vitro and systems-level models, enabling reproducible modulation of cholinergic signaling (acetyl-angiotensinogen.com).
• Recommended storage at -20°C preserves compound stability for at least 6 months; solutions should be used promptly to ensure full efficacy (APExBIO).

Applications, Limits & Misconceptions

Otilonium Bromide is extensively used to model gastrointestinal motility disorders, dissect neuronal cholinergic pathways, and study receptor-mediated contractility in smooth muscle research. Its use extends to high-throughput screening of antimuscarinic effects and as a reference compound in comparative pharmacology studies. However, it is strictly limited to non-clinical, research-only workflows. It does not serve as a therapeutic intervention or diagnostic tool. The compound’s selectivity does not extend to nicotinic AChRs, nor does it inhibit unrelated neurotransmitter systems at typical working concentrations.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not intended for diagnostic or therapeutic use in humans or animals (APExBIO).
• It does not inhibit nicotinic acetylcholine receptors or non-cholinergic pathways.
• Degradation may occur if solutions are stored above -20°C or used after prolonged periods; efficacy is not guaranteed outside recommended storage conditions.
• It is not a suitable agent for antiviral research against NSP15 of SARS-CoV-2, as its mechanism does not target viral proteins (Vijayan et al., 2021).
• Interpretation of contractility data must account for concentration and receptor subtype specificity; off-target effects are rare but possible at supra-physiological doses.

Workflow Integration & Parameters

For in vitro pharmacology, Otilonium Bromide is typically dissolved in DMSO, water, or ethanol, with working concentrations tailored to the receptor or tissue model in use. The high solubility streamlines preparation for dose-response, receptor binding, and functional assays. APExBIO supplies B1607 at ≥98% purity, supporting workflows that demand high reproducibility and low background interference (APExBIO). For advanced systems-level analyses, Otilonium Bromide’s robust inhibition profile enables integration with electrophysiology, contractility, or imaging platforms. Researchers seeking extended mechanistic perspectives can reference this mechanistic review, which details receptor subtype specificity and translational potential, expanding on the current article’s experimental focus. For streamlined workflows and comparison with other antimuscarinic agents in complex models, see the precision integration guide—the present article updates recommended storage and solution stability guidelines for B1607.

Conclusion & Outlook

Otilonium Bromide, as supplied by APExBIO, provides a validated, high-purity tool for neuroscience and smooth muscle research applications. Its precise antimuscarinic inhibition and superior solubility profile support both standard and advanced workflows targeting cholinergic signaling and gastrointestinal motility models. Researchers are advised to adhere strictly to recommended storage and handling guidelines for optimal performance. For extended insights into systems-level receptor pharmacology and translational applications, consult recent reviews and mechanistic studies (a-317491.com), which this article clarifies with updated evidence and practical workflow parameters.